CRBN (Protein cereblon) variants and mutations
CRBN (also known as Protein cereblon) is a human protein-coding gene encoding a protein cereblon protein. It determines substrate recognition for the CRL4-CRBN ubiquitin ligase and thereby controls degradation of selected cellular proteins. Thalidomide and related drugs bind CRBN and redirect the ligase toward new substrates, a mechanism central to their therapeutic and teratogenic effects. This analysis covers 716 CRBN variants and mutations. Of these, 81% have computational variant effect predictions. Disease context includes plasma cell myeloma, autosomal recessive non-syndromic intellectual disability, and myelodysplastic syndrome. Example CRBN variants include A2P, A2S, and A2V.
Variant analysis overview
- Gene: CRBN
- Protein: Protein cereblon
- UniProt accession: Q96SW2
- Organism: Homo sapiens
- Variants analyzed: 716
- Variant scope: all variants
- Completed: 2026-08-04
Variant and mutation evidence
- Variant composition: 524 unspecified-consequence records; 1 stop retained variant; 4 stop lost; 25 frameshift variants; 46 synonymous variants; 94 missense variants; 12 stop-gained variants; 6 in-frame insertions; 1 protein altering variant; 1 in-frame deletions; 1 splice-region variants; 1 substitution
- Prediction scores: 582 variants have prediction scores (81% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: plasma cell myeloma, autosomal recessive non-syndromic intellectual disability, myelodysplastic syndrome, congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developme, follicular lymphoma, mantle cell lymphoma, retinitis pigmentosa and erythrocytic microcytosis, immune system disorder, anemia, hereditary disease, Retinal dystrophy, diffuse large B-cell lymphoma.
Protein structure and variant hotspots
- Protein features: 2 domains; 7 binding sites; 1 post-translational modification sites.
- Structural context: 492 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CRBN variants
Examples include A2P, A2S, A2V, G3C, G3D, G3R, G3S, E4Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2P (p.Ala2Pro), gnomAD rs1156956523, REVEL 0.15, CADD 29.50
- A2S (p.Ala2Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A2V (p.Ala2Val), TOPMed rs1707995715, REVEL 0.16, CADD 27.00
- G3C (p.Gly3Cys), ExAC rs757719993, TOPMed rs757719993, gnomAD rs757719993, Uncertain significance
- G3D (p.Gly3Asp), rs1183222102, NCI-TCGA Cosmic COSV5164, gnomAD rs1183222102, REVEL 0.05, CADD 15.70, Variant assessed as somatic; moderate impact.
- G3R (p.Gly3Arg), rs757719993, ClinGen CA351452482, ClinVar RCV000504122, ExAC rs757719993, REVEL 0.12, CADD 25.30, Uncertain significance, not specified
- G3S (p.Gly3Ser), rs757719993, ClinGen CA2229446, ClinVar RCV002737071, ExAC rs757719993, REVEL 0.07, CADD 23.30, Uncertain significance, Inborn genetic diseases
- E4Q (p.Glu4Gln), Ensembl rs1575106229, REVEL 0.17, CADD 23.50
- G5* (p.Gly5Ter), NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, TOPMed rs1250225494, gnomAD rs1250225494, Variant assessed as somatic; high impact.
- G5E (p.Gly5Glu), 1000Genomes rs143087756, ESP rs143087756, ExAC rs143087756, TOPMed rs143087756, REVEL 0.15, CADD 15.80
- G5R (p.Gly5Arg), TOPMed rs1250225494, gnomAD rs1250225494, REVEL 0.12, CADD 23.50
- G5V (p.Gly5Val), NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, REVEL 0.08, CADD 22.20, Variant assessed as somatic; moderate impact.
- D6E (p.Asp6Glu), TOPMed rs1259464925, gnomAD rs1259464925, REVEL 0.06, CADD 0.66, Uncertain significance, Inborn genetic diseases
- D6G (p.Asp6Gly), TOPMed rs908451988, gnomAD rs908451988, REVEL 0.09, CADD 22.60
- D6H (p.Asp6His), rs756440147, ClinGen CA2229442, ClinVar RCV000502694, ExAC rs756440147, REVEL 0.10, CADD 22.70, Uncertain significance, not specified
- D6N (p.Asp6Asn), ExAC rs756440147, TOPMed rs756440147, gnomAD rs756440147, REVEL 0.07, CADD 22.30, Uncertain significance
- D6Y (p.Asp6Tyr), cosmic curated COSV51642, ExAC rs756440147, TOPMed rs756440147, gnomAD rs756440147, REVEL 0.08, CADD 23.90, Uncertain significance
- Q7E (p.Gln7Glu), ExAC rs752968990, TOPMed rs752968990, gnomAD rs752968990, REVEL 0.08, CADD 13.00, Uncertain significance, Inborn genetic diseases
- Q7H (p.Gln7His), ExAC rs774302109, TOPMed rs774302109, gnomAD rs774302109, REVEL 0.07, CADD 15.00
- Q7K (p.Gln7Lys), rs752968990, ExAC rs752968990, TOPMed rs752968990, gnomAD rs752968990, REVEL 0.04, CADD 16.70, Variant assessed as somatic; moderate impact.
- Q7L (p.Gln7Leu), 1000Genomes rs192011911, ExAC rs192011911, TOPMed rs192011911, gnomAD rs192011911, REVEL 0.03, CADD 12.90, Uncertain significance
- Q7R (p.Gln7Arg), rs192011911, ClinGen CA2229439, ClinVar RCV000501243, ClinVar RCV004023366, REVEL 0.04, CADD 9.69, Uncertain significance, not specified; Inborn genetic diseases
- Q8* (p.Gln8Ter), TOPMed rs1707992925, gnomAD rs1707992925, CADD 39.00
- Q8P (p.Gln8Pro), ESP rs147395766, ExAC rs147395766, TOPMed rs147395766, gnomAD rs147395766, REVEL 0.05, CADD 17.80
- Q8R (p.Gln8Arg), ESP rs147395766, ExAC rs147395766, TOPMed rs147395766, gnomAD rs147395766, REVEL 0.04, CADD 18.20
- D9A (p.Asp9Ala), ESP rs148285043, ExAC rs148285043, TOPMed rs148285043, gnomAD rs148285043, REVEL 0.02, CADD 24.30
- D9E (p.Asp9Glu), rs776519022, cosmic curated COSV99214, ExAC rs776519022, TOPMed rs776519022, REVEL 0.16, CADD 22.40, Conflicting interpretations, Inborn genetic diseases; not provided
- D9G (p.Asp9Gly), ESP rs148285043, ExAC rs148285043, TOPMed rs148285043, gnomAD rs148285043, REVEL 0.06, CADD 23.80
- D9H (p.Asp9His), Ensembl rs1559261365
- A10G (p.Ala10Gly), rs137880766, ClinGen CA2229429, ClinVar RCV001334905, 1000Genomes rs137880766, REVEL 0.08, CADD 23.10, Uncertain significance, Intellectual disability, autosomal recessive 2
- A10P (p.Ala10Pro), rs768452189, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, ExAC rs768452189, REVEL 0.06, CADD 22.40, Uncertain significance, Inborn genetic diseases
- A10S (p.Ala10Ser), ExAC rs768452189, TOPMed rs768452189, gnomAD rs768452189, REVEL 0.09, CADD 18.70, Uncertain significance, Inborn genetic diseases
- A10V (p.Ala10Val), 1000Genomes rs137880766, ESP rs137880766, ExAC rs137880766, TOPMed rs137880766, REVEL 0.08, CADD 22.80, Uncertain significance, Inborn genetic diseases
- A11E (p.Ala11Glu), gnomAD rs866123640, REVEL 0.04, CADD 18.90
- A11G (p.Ala11Gly), gnomAD rs866123640, REVEL 0.04, CADD 22.50
- A11S (p.Ala11Ser), rs749799282, ClinGen CA351452444, ClinVar RCV004367175, ExAC rs749799282, REVEL 0.02, CADD 19.50, Uncertain significance, Inborn genetic diseases
- A11T (p.Ala11Thr), rs749799282, ClinGen CA2229426, ClinVar RCV004367174, ExAC rs749799282, REVEL 0.02, CADD 21.80, Likely benign, Inborn genetic diseases
- A11V (p.Ala11Val), gnomAD rs866123640, REVEL 0.05, CADD 22.60
- H12D (p.His12Asp), rs797045482, ClinGen CA68735844, ClinVar RCV002688072, TOPMed rs797045482, REVEL 0.04, CADD 16.40, Uncertain significance, Inborn genetic diseases
- H12N (p.His12Asn), TOPMed rs797045482, gnomAD rs797045482, REVEL 0.04, CADD 16.20, Uncertain significance
- H12P (p.His12Pro), rs1392453549, ClinGen CA351452439, ClinVar RCV003277822, TOPMed rs1392453549, REVEL 0.33, CADD 22.30, Uncertain significance, Inborn genetic diseases
- H12Q (p.His12Gln), TOPMed rs1205324698, gnomAD rs1205324698, REVEL 0.07, CADD 18.70
- H12Y (p.His12Tyr), rs797045482, ClinGen CA206671, ClinVar RCV000193291, TOPMed rs797045482, REVEL 0.10, CADD 19.70, Uncertain significance, not specified
- N13S (p.Asn13Ser), NCI-TCGA Cosmic COSV5164, cosmic curated COSV51641, Ensembl rs1707990695, REVEL 0.09, CADD 24.00, Variant assessed as somatic; moderate impact.
- N13T (p.Asn13Thr), Ensembl rs1707990695, REVEL 0.09, CADD 24.80
- M14L (p.Met14Leu), rs753095651, ExAC rs753095651, TOPMed rs753095651, gnomAD rs753095651, REVEL 0.16, CADD 25.00, Uncertain significance, Intellectual disability, autosomal recessive 2; Inborn genetic diseases
- M14R (p.Met14Arg), ExAC rs781471783, gnomAD rs781471783, REVEL 0.27, CADD 32.00
- M14T (p.Met14Thr), ExAC rs781471783, gnomAD rs781471783
- M14V (p.Met14Val), rs753095651, ClinGen CA2229425, ClinVar RCV002992067, ExAC rs753095651, REVEL 0.13, CADD 24.40, Uncertain significance, Inborn genetic diseases
- N16K (p.Asn16Lys), Ensembl rs2126072706, Uncertain significance, not provided
- N16T (p.Asn16Thr), ExAC rs755209533, gnomAD rs755209533, REVEL 0.09, CADD 30.00
- N16Y (p.Asn16Tyr), TOPMed rs1255060716, gnomAD rs1255060716, REVEL 0.13, CADD 31.00
- H17P (p.His17Pro), cosmic curated COSV51642, ExAC rs200222965, gnomAD rs200222965, REVEL 0.14, CADD 23.70
- H17Q (p.His17Gln), gnomAD rs1488527536, REVEL 0.07, CADD 19.30
- P19A (p.Pro19Ala), ESP rs374934479, ExAC rs374934479
- P19L (p.Pro19Leu), gnomAD rs1343791001, REVEL 0.04, CADD 22.80
- P19R (p.Pro19Arg), gnomAD rs1343791001, REVEL 0.03, CADD 22.50
- P19S (p.Pro19Ser), rs374934479, cosmic curated COSV51642, ESP rs374934479, ExAC rs374934479, AlphaMissense 0.09, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- P22L (p.Pro22Leu), ExAC rs760313831, TOPMed rs760313831, gnomAD rs760313831, REVEL 0.26, CADD 29.40
- P22R (p.Pro22Arg), ExAC rs760313831, TOPMed rs760313831, gnomAD rs760313831
- P22S (p.Pro22Ser), TOPMed rs1303398008, gnomAD rs1303398008, REVEL 0.06, CADD 23.30
- A23T (p.Ala23Thr), ExAC rs775177379, gnomAD rs775177379, REVEL 0.12, CADD 33.00
- E24D (p.Glu24Asp), rs2471487638, ClinGen CA351453919, ClinVar RCV002920425, Uncertain significance, Inborn genetic diseases
- S25N (p.Ser25Asn), ExAC rs770418684, gnomAD rs770418684, REVEL 0.20, CADD 10.40
- S25R (p.Ser25Arg), Ensembl rs199607080, REVEL 0.03, CADD 19.80
- E27A (p.Glu27Ala), Ensembl rs1575101849
- E27D (p.Glu27Asp), TOPMed rs1707784875, Uncertain significance, not provided
- E27K (p.Glu27Lys), TOPMed rs961091349, gnomAD rs961091349, REVEL 0.06, CADD 23.90, Uncertain significance, Inborn genetic diseases
- E28D (p.Glu28Asp), gnomAD rs1238628912, REVEL 0.09, CADD 17.10, Uncertain significance, not provided
- E28G (p.Glu28Gly), Ensembl rs1707784619
- E28K (p.Glu28Lys), gnomAD rs1280166278, REVEL 0.09, CADD 23.30
- D29G (p.Asp29Gly), NCI-TCGA TCGA novel, REVEL 0.15, CADD 22.60, Variant assessed as somatic; moderate impact.
- D29H (p.Asp29His), Ensembl rs971571494, REVEL 0.12, CADD 24.10
- E30K (p.Glu30Lys), rs78564552, ClinGen CA206506, ClinVar RCV000193191, ClinVar RCV000224199, REVEL 0.08, CADD 23.20, Conflicting interpretations, not specified; not provided
- M31V (p.Met31Val), ExAC rs768947812, gnomAD rs768947812, REVEL 0.13, CADD 15.40
- E32* (p.Glu32Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E32K (p.Glu32Lys), rs1397046310, ClinGen CA351453865, ClinVar RCV003148307, ClinVar RCV006342919, REVEL 0.15, CADD 24.90, Uncertain significance, Intellectual disability, autosomal recessive 2; Inborn genetic diseases
- E32V (p.Glu32Val), gnomAD rs1405796444, REVEL 0.28, CADD 28.00
- V33F (p.Val33Phe), TOPMed rs1335338146, gnomAD rs1335338146, REVEL 0.13, CADD 19.60
- D35E (p.Asp35Glu), TOPMed rs1463720950, gnomAD rs1463720950, REVEL 0.09, CADD 20.20
- D35N (p.Asp35Asn), ExAC rs780239031, TOPMed rs780239031, gnomAD rs780239031, REVEL 0.17, CADD 24.20
- Q36* (p.Gln36Ter), TOPMed rs1296603799, gnomAD rs1296603799, CADD 38.00
- Q36H (p.Gln36His), TOPMed rs898710726
- Q36R (p.Gln36Arg), Ensembl rs1013178602, REVEL 0.05, CADD 20.60
- S38R (p.Ser38Arg), gnomAD rs1468137903
- S38T (p.Ser38Thr), gnomAD rs1157434006, REVEL 0.03, CADD 14.80
- E40G (p.Glu40Gly), ESP rs367782361, ExAC rs367782361, TOPMed rs367782361, gnomAD rs367782361, REVEL 0.09, CADD 23.00
- E40K (p.Glu40Lys), gnomAD rs1369903395
- E40V (p.Glu40Val), ESP rs367782361, ExAC rs367782361, TOPMed rs367782361, gnomAD rs367782361
- K42* (p.Lys42Ter), rs2126069389, ClinGen CA351453792, ClinVar RCV002252831, Ensembl rs2126069389, Likely pathogenic
- K42R (p.Lys42Arg), ExAC rs746028499, gnomAD rs746028499
- P44R (p.Pro44Arg), ExAC rs757381730, gnomAD rs757381730, REVEL 0.26, CADD 26.20
- P44T (p.Pro44Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- N45D (p.Asn45Asp), TOPMed rs1348628352, gnomAD rs1348628352, REVEL 0.06, CADD 20.30
- I46F (p.Ile46Phe), gnomAD rs1286236549
- I46V (p.Ile46Val), gnomAD rs1286236549
- I47M (p.Ile47Met), ExAC rs753877802, gnomAD rs753877802, REVEL 0.14, CADD 20.60
- I47V (p.Ile47Val), Ensembl rs1707781639, REVEL 0.11, CADD 21.00
- N48H (p.Asn48His), gnomAD rs1382508167, REVEL 0.15, CADD 25.40
- T51P (p.Thr51Pro), ExAC rs764115779, gnomAD rs764115779, REVEL 0.23, CADD 22.70
- S52G (p.Ser52Gly), rs1707781160, ClinGen CA351453723, ClinVar RCV002959343, Ensembl rs1707781160, AlphaMissense 0.26, MetaLR 0.39, Uncertain significance, Inborn genetic diseases
- P54L (p.Pro54Leu), Ensembl rs1707780977, REVEL 0.79, CADD 29.10
- P54S (p.Pro54Ser), Ensembl rs866178945, REVEL 0.51, CADD 27.80
- T58A (p.Thr58Ala), TOPMed rs1707780718
- Y59H (p.Tyr59His), gnomAD rs1308449938, REVEL 0.67, CADD 26.50
- L60V (p.Leu60Val), ExAC rs760002909, gnomAD rs760002909, REVEL 0.24, CADD 23.30
- G61A (p.Gly61Ala), TOPMed rs1707741028, gnomAD rs1707741028, REVEL 0.47, CADD 23.40
- G61C (p.Gly61Cys), Ensembl rs1559257423, REVEL 0.64, CADD 24.80
- A62S (p.Ala62Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A62T (p.Ala62Thr), TOPMed rs928255811, gnomAD rs928255811, REVEL 0.03, CADD 7.57
- A62V (p.Ala62Val), rs774818392, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, ExAC rs774818392, REVEL 0.10, CADD 17.10, Variant assessed as somatic; moderate impact.
- D63H (p.Asp63His), cosmic curated COSV51640, gnomAD rs1284446935, REVEL 0.22, CADD 24.30
- D63V (p.Asp63Val), TOPMed rs1222437889, gnomAD rs1222437889, REVEL 0.59, CADD 25.10
- M64I (p.Met64Ile), Ensembl rs1707740047
- M64T (p.Met64Thr), ExAC rs771285272, TOPMed rs771285272, gnomAD rs771285272, REVEL 0.25, CADD 23.30
- M64V (p.Met64Val), TOPMed rs11556967
- E65K (p.Glu65Lys), NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, Variant assessed as somatic; moderate impact.
- E66* (p.Glu66Ter), NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, Variant assessed as somatic; high impact.
- E66A (p.Glu66Ala), TOPMed rs1319714037, gnomAD rs1319714037, REVEL 0.39, CADD 27.50
- F67L (p.Phe67Leu), ExAC rs777971005, gnomAD rs777971005, REVEL 0.27, CADD 23.40
- F67Y (p.Phe67Tyr), TOPMed rs1707739692, REVEL 0.20, CADD 22.30
- H68R (p.His68Arg), rs1312427130, ClinGen CA351453603, ClinVar RCV004367171, gnomAD rs1312427130, REVEL 0.17, CADD 23.10, Uncertain significance, Inborn genetic diseases
- R70S (p.Arg70Ser), Ensembl rs753021634, REVEL 0.29, CADD 23.40
- T71A (p.Thr71Ala), ExAC rs769762310, gnomAD rs769762310
- H73L (p.His73Leu), gnomAD rs1429956875, REVEL 0.57, CADD 23.00
- H73Q (p.His73Gln), 1000Genomes rs1045309, ESP rs1045309, ExAC rs1045309, TOPMed rs1045309, REVEL 0.28, CADD 8.73, Benign
- D74N (p.Asp74Asn), cosmic curated COSV10875, gnomAD rs1480157421, REVEL 0.30, CADD 25.70
- D76N (p.Asp76Asn), rs370224981, ClinGen CA2229335, cosmic curated COSV99214, ClinVar RCV004367172, REVEL 0.27, CADD 22.70, Uncertain significance, Inborn genetic diseases
- D76Y (p.Asp76Tyr), ESP rs370224981, ExAC rs370224981, TOPMed rs370224981, gnomAD rs370224981, REVEL 0.38, CADD 25.70, Uncertain significance
- C78Y (p.Cys78Tyr), ExAC rs779756864, gnomAD rs779756864, REVEL 0.27, CADD 23.10
- Q79* (p.Gln79Ter), rs377356443, ClinGen CA2229333, ClinVar RCV001559874, ESP rs377356443, CADD 40.00, Likely pathogenic
- V80A (p.Val80Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V80G (p.Val80Gly), Ensembl rs1575100670
- V80L (p.Val80Leu), TOPMed rs1202909740, gnomAD rs1202909740, REVEL 0.06, CADD 18.80
- V80M (p.Val80Met), TOPMed rs1202909740, gnomAD rs1202909740, REVEL 0.09, CADD 20.50, Uncertain significance, Inborn genetic diseases
- I81T (p.Ile81Thr), Ensembl rs1707737789, REVEL 0.58, CADD 26.30
- P82A (p.Pro82Ala), cosmic curated COSV10457, gnomAD rs1444481708, REVEL 0.70, CADD 26.20
- P82L (p.Pro82Leu), gnomAD rs1264367096, REVEL 0.71, CADD 31.00
- V83F (p.Val83Phe), gnomAD rs1203528010, REVEL 0.33, CADD 25.30
- V83I (p.Val83Ile), gnomAD rs1203528010, REVEL 0.15, CADD 22.90, Uncertain significance, Inborn genetic diseases
- L84F (p.Leu84Phe), ExAC rs201449042, gnomAD rs201449042, REVEL 0.28, CADD 24.40
- L84P (p.Leu84Pro), ExAC rs764868386, gnomAD rs764868386
- P85R (p.Pro85Arg), TOPMed rs1707737105, REVEL 0.36, CADD 24.40, Uncertain significance, Inborn genetic diseases
- P85S (p.Pro85Ser), NCI-TCGA TCGA novel, REVEL 0.26, CADD 23.50, Variant assessed as somatic; moderate impact.
- Q86L (p.Gln86Leu), Ensembl rs370955273
- M88T (p.Met88Thr), NCI-TCGA TCGA novel, gnomAD rs1707736712, REVEL 0.08, CADD 16.40, Variant assessed as somatic; moderate impact.
- M88V (p.Met88Val), ExAC rs753340354, TOPMed rs753340354, gnomAD rs753340354, REVEL 0.08, CADD 13.30
- M89I (p.Met89Ile), rs760055652, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, ExAC rs760055652, REVEL 0.05, CADD 21.00, Variant assessed as somatic; moderate impact.
- M89V (p.Met89Val), ExAC rs768172056, TOPMed rs768172056, gnomAD rs768172056, REVEL 0.08, CADD 13.40
- I90M (p.Ile90Met), TOPMed rs1423594298, gnomAD rs1423594298, REVEL 0.08, CADD 15.00
- P93T (p.Pro93Thr), gnomAD rs1336003474, REVEL 0.91, CADD 26.50
- G94R (p.Gly94Arg), rs769962148, NCI-TCGA Cosmic COSV5164, cosmic curated COSV51640, ExAC rs769962148, REVEL 0.76, CADD 27.50, Variant assessed as somatic; moderate impact.
- T96A (p.Thr96Ala), rs797045481, ClinGen CA209444, ClinVar RCV000194943, Ensembl rs797045481, AlphaMissense 0.47, MetaLR 0.29, Uncertain significance, not specified
- L97* (p.Leu97Ter), TOPMed rs1317907576, gnomAD rs1317907576, CADD 37.00
- Q100H (p.Gln100His), rs781289482, ClinGen CA2229320, ClinVar RCV004367173, 1000Genomes rs781289482, REVEL 0.04, CADD 16.30, Uncertain significance, Inborn genetic diseases
- Q100L (p.Gln100Leu), TOPMed rs1344111578
- L101V (p.Leu101Val), TOPMed rs1285884277, REVEL 0.24, CADD 26.00
- H103R (p.His103Arg), TOPMed rs1376964266
- H103Y (p.His103Tyr), NCI-TCGA Cosmic COSV5164, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, Variant assessed as somatic; moderate impact.
- P104H (p.Pro104His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P104R (p.Pro104Arg), gnomAD rs1164960278, REVEL 0.53, CADD 27.10
- Q105K (p.Gln105Lys), Ensembl rs1232438561
- E106* (p.Glu106Ter), NCI-TCGA Cosmic COSV5163, Variant assessed as somatic; high impact.
- E106K (p.Glu106Lys), rs758183266, NCI-TCGA Cosmic COSV5163, cosmic curated COSV51639, ExAC rs758183266, REVEL 0.23, CADD 27.10, Variant assessed as somatic; moderate impact.
- E106Q (p.Glu106Gln), ExAC rs758183266, gnomAD rs758183266
- M109I (p.Met109Ile), TOPMed rs1226821915
- M109L (p.Met109Leu), TOPMed rs1707734095, REVEL 0.10, CADD 22.40
- V110L (p.Val110Leu), TOPMed rs1460337269, gnomAD rs1460337269, REVEL 0.12, CADD 22.30
- V110M (p.Val110Met), TOPMed rs1460337269, gnomAD rs1460337269, REVEL 0.09, CADD 19.60
- R111Q (p.Arg111Gln), rs151127854, cosmic curated COSV51639, ESP rs151127854, ExAC rs151127854, REVEL 0.23, CADD 25.60, Variant assessed as somatic; moderate impact.
- R111W (p.Arg111Trp), rs756895773, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, ExAC rs756895773, REVEL 0.50, CADD 33.00, Variant assessed as somatic; moderate impact.
- N112S (p.Asn112Ser), ExAC rs760180642, gnomAD rs760180642, REVEL 0.10, CADD 16.40
- L113S (p.Leu113Ser), NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, Variant assessed as somatic; moderate impact.
- Q115* (p.Gln115Ter), TOPMed rs966130308
- Q115E (p.Gln115Glu), TOPMed rs966130308, REVEL 0.13, CADD 21.90
- Q115H (p.Gln115His), TOPMed rs1707732923, gnomAD rs1707732923, REVEL 0.17, CADD 25.20
- K116N (p.Lys116Asn), ESP rs145695200, ExAC rs145695200, gnomAD rs145695200, REVEL 0.13, CADD 17.00
- D117A (p.Asp117Ala), TOPMed rs1483237189, gnomAD rs1483237189, REVEL 0.58, CADD 28.90
- D117E (p.Asp117Glu), ExAC rs763201952, gnomAD rs763201952, REVEL 0.41, CADD 22.90
- D117N (p.Asp117Asn), NCI-TCGA Cosmic COSV1043, NCI-TCGA Cosmic COSV9921, cosmic curated COSV99214, Variant assessed as somatic; moderate impact.
Public CRBN analysis runs
- CRBN analysis run — CRBN (716 variants) — completed 2026-08-04